Could a common supplement help rare disease? small study begins

NCT ID NCT07572825

NEW Not yet recruiting Knowledge-focused Sponsor: Eva Morava-Kozicz Source: ClinicalTrials.gov ↗

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This study aims to see if the dietary supplement NMN is safe for people with a rare genetic condition called DHDDS-CDG. Eight participants aged 4 and older will take NMN for 6 months, with a follow-up at 12 months. The main goal is to check for side effects and gather information to help doctors decide if NMN is worth recommending.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONGENITAL DISORDER OF GLYCOSYLATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icahn School of Medicine at Mount Sinai

    New York, New York, 10029, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.